LVCLF Stock UPDATES Living Cell Technologies Limited (LVCLF)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Living Cell Technologies Limited (LVCLF) 0.0508 $LVCLF

Hearing Disorders - Pipeline Review, H1 2014
M2 - Thu Jul 03, 5:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7w63tx/hearing_disorders) has announced the addition of the "Hearing Disorders - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hearing Disorders, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hearing Disorders and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Hearing Disorders - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Hearing Disorders pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Adherex Technologies - Quark Pharmaceuticals - Novartis - Living Cell Technologies - Fate Therapeutics - Sound Pharmaceuticals - Pharmicell - Otologic Pharmaceutics - UniQure - AudioCure For more information visit http://www.researchandmarkets.com/research/7w..._disorders

'First-in-man' Implant of Regenerative Cell Therapy in Parkinson's Disease
PR Newswire - Thu Sep 19, 9:36PM CDT
Living Cell Technologies Limited (LCT) today announced that the first patient has been successfully implanted in the Phase I clinical trial of the regenerative cell therapy NTCELL(R) - a potential treatment for Parkinson's disease.

Hemophilia - Pipeline Review, H2 2013
M2 - Tue Sep 10, 3:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rvbm6c/hemophilia) has announced the addition of the "Hemophilia - Pipeline Review, H2 2013" report to their offering. 'Hemophilia - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Hemophilia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hemophilia. Scope - A snapshot of the global therapeutic scenario for Hemophilia. - A review of the Hemophilia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Hemophilia pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Baxter International Inc. Biogen Idec Inc. AstraZeneca PLC Nektar Therapeutics Cangene Corporation Lentigen Corporation Sangamo BioSciences, Inc. Pharming Group N.V. Novo Nordisk A/S BioMarin Pharmaceutical Inc. Chugai Pharmaceutical Co. Ltd Dong-A Pharmaceutical Co., Ltd. GTC Biotherapeutics, Inc. Octapharma AG Pain Therapeutics, Inc. Pfizer Inc. Bayer AG Living Cell Technologies Limited PROLOR Biotech, Inc. ReGenX Biosciences, LLC Alnylam Pharmaceuticals, Inc CSL Limited and many more... For more information visit http://www.researchandmarkets.com/research/rvbm6c/hemophilia About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Huntington's Disease - Pipeline Review, H2 2013 Reviews Key Players Involved In the Therapeutic Development for Huntington's Disease
M2 - Thu Sep 05, 9:42AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6nbttk/huntingtons) has announced the addition of the "Huntington's Disease - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Huntington's Disease - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Huntington's Disease, complete with latest updates, and special features on late-stage and discontinued projects. Huntington's Disease - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Huntington's Disease. - A review of the Huntington's Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Huntington's Disease pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: Normal 0 false false false MicrosoftInternetExplorer4 - ACADIA Pharmaceuticals Inc. - Accera, Inc. - Auspex Pharmaceuticals - BrainStorm Cell Therapeutics Inc. - Ceregene, Inc. - CrystalGenomics, Inc. - GW Pharmaceuticals plc - Galenea Corp. - Genzyme Corporation - GlaxoSmithKline plc - Hadasit Medical Research Services & Development Ltd - Ipsen S.A. - Isis Pharmaceuticals, Inc. - KineMed, Inc. - Living Cell Technologies Limited - Neuralstem, Inc. - Omeros Corporation - Oryzon - Pfizer Inc. - Prana Biotechnology Limited - Raptor Pharmaceuticals Corp. - SCYNEXIS, Inc. - Siena Biotech S.p.A. - Suven Life Sciences Ltd. - Teva Pharmaceutical Industries Limited - The Avicena Group, Inc. - Varinel, Inc. - Vertex Pharmaceuticals Incorporated - Vybion, Inc. - Wellstat Therapeutics Corporation For more information visit http://www.researchandmarkets.com/research/6n...untingtons About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Huntington's Disease - Pipeline Review, H1 2013
M2 - Wed Apr 17, 4:33AM CDT
Research and Markets has announced the addition of the "Huntington's Disease - Pipeline Review, H1 2013" report to their offering. 'Huntington's Disease - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Huntington's Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Huntington's Disease. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Huntington's Disease. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Huntington's Disease pipeline depth and focus of Indicatio




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Five SEAL Medal of Honor Signatures, One Charity Lot

Updated Category News Views 35

A single rifle can carry a staggering amount of meaning when the names on it belong to all five living U.S. Navy SEAL Medal of Honor recipients. Rock Island Auction Company plans to offer that one-of-a-kind custom precision rifle during its December 4–6, 2026 Premier Firearms Auction, and the financial arrangement is unusually clean: 100% of proceeds are slated for the...

Continue Reading
Jeff Stern Turns Travel Photography Into Full Attention

Updated Category News Views 57

A cancelled photography conference in March 2020 sent Jeff Stern toward the American Southwest, and that detour eventually became A Change of Scenery. Frankly, that origin has more grit than the usual polished creative-origin tale. While much of the world had stopped moving, Stern went alone, stood at White Pocket beneath a cobalt sky, and began reconsidering what he...

Continue Reading
TDH's First-Half Revenue Grew, but Margins Vanished

Updated Category News Views 91

A rental business can add tenants and still march backward, and TDH Holdings just demonstrated the ugly math. For the six months ended June 30, 2026, revenue from continuing operations rose 26.45% to $0.74 million. That is the pleasant number, and it deserves exactly one polite nod. Everything beneath it looks far less comfortable: costs climbed faster than revenue, gross...

Continue Reading
Adecco Finds AI Value Depends on Better Work Redesign

Updated Category News Views 74

A shiny AI license is not a productivity strategy, and Adecco's latest workforce survey puts some hard numbers behind that irritation. The company surveyed 40,500 workers in 36 countries for its seventh Global Workforce of the Future report, released November 19, 2026. Its central finding is disarmingly sensible: AI produces more when companies rebuild the work around it...

Continue Reading
Alphabet Lawsuit Puts Gemini Delays Under a Microscope

Updated Category News Views 151

July’s twin punches to Alphabet shares were not the sort of wobble investors can casually shrug off. First came a report on July 16 that Google was months behind on Gemini 3.5 Pro, its flagship AI model, after disappointing results from updated training data. Then came the harder financial reality a week later: a much larger 2026 capital-spending plan, negative...

Continue Reading
First Horizon Opens Its Charlotte Office in South End

Updated Category News Views 14

A Building Is Not a Balance Sheet Charlotte got a fresh First Horizon sign at 110 East Boulevard on Nov. 19, 2026, and that is a sensible move, not a magic trick. The bank has officially opened a corporate office in the city’s South End neighborhood, positioning the team to develop client relationships across the Charlotte area and broaden its regional footprint. That...

Continue Reading
Makera A1S Tests the Desktop CNC Metal-Cutting Promise

Updated Category News Views 84

Aluminum chips are where desktop-machine marketing stops bluffing, and Makera is leaning right into that test with the A1S. The company opened global pre-orders on November 18 for a machine aimed squarely at the awkward middle ground: users who have outgrown entry-level hobby gear but do not have room, budget, or patience for a full industrial setup. That is a real market...

Continue Reading
PenFed’s Toys for Tots Drive Targets Holiday Gift Gaps

Updated Category News Views 69

A missing present under a tree is not a statistic anybody ought to glide past. PenFed Credit Union has opened its annual Toys for Tots collection across Washington-region branches, taking new, unwrapped toys through December 8 at 1:00 p.m. ET. The useful detail, and frankly the one worth remembering when people default to buying the easiest shiny thing on a shelf, is...

Continue Reading
Why Professional Collaboration May Matter More in AI

Updated Category News Views 43

Three smart professionals can still hand a client a mess when nobody owns the handoff. That unglamorous reality sits behind the Professional Collaboration Institute, or PCI, which Sarano and Brooke Kelley plan to launch in a virtual briefing on December 2. The outfit wants to turn cross-profession coordination into a teachable, measurable discipline rather than leave it...

Continue Reading
Royce Global Trust's Discount Is Still the Whole Debate

Updated Category News Views 90

A $3.03 gap is staring investors right in the face. As of October 31, 2026, Royce Global Trust carried a net asset value of $17.51 per share while the market price sat at $14.48. That works out to roughly a 17.3% discount to NAV, and with a closed-end fund, that discount is not some footnote shoved under the table. It is a major part of the return story, good or bad. The...

Continue Reading

Top 5 Most Recently Viewed Articles

Light AI Secures Major Over-Allotment and Begins Trading on Cboe

Updated Category News Views 160

Light AI Announces Successful Closure of Over-Allotment Option Light AI Inc. (formerly known as Mojave Brands Inc.) (CBOE CA: ALGO) is thrilled to share recent developments regarding its over-allotment option, which saw a successful full exercise by the Agents. This step resulted in the purchase of an additional 2,757,000 units, amounting to an impressive gross proceeds...

Continue Reading
U.S. Stock Market Futures Decline Ahead of Key Economic Data

Updated Category News Views 290

U.S. Stock Market Futures Show Caution Ahead of Economic Reports Recently, U.S. stock index futures have taken a downward turn as traders adopt a cautious stance. With a series of economic data reports set to be released this week, the financial markets are bracing for potential impacts on the Federal Reserve's monetary policy in the near future. Market Performance in...

Continue Reading
RUSH's 2026 Tour: Celebrating Legacy and New Beginnings

Updated Category News Views 329

RUSH's 2026 Tour: A Celebration of Music and Legacy Geddy Lee and Alex Lifeson are set to celebrate over 50 years of RUSH's musical journey as they announce a special headline tour for 2026, named the Fifty Something Tour. This tour not only commemorates the incredible music and legacy of RUSH, but also pays tribute to their late drummer and lyricist Neil Peart, whose...

Continue Reading
Star Hats & Embroidery Shines on CBS National Network

Updated Category News Views 126

Star Hats & Embroidery Takes Center Stage on National Television Star Hats & Embroidery is proud to announce its recent television features that highlight the innovative products and services they offer. Following an exciting showcase on CBS's Las Vegas Now Lifestyle TV Show, the brand has appeared in numerous segments across the nation, captivating audiences everywhere....

Continue Reading
Celebrate Culture and Community at Ohkay Hotel's Lowrider Show

Updated Category News Views 350

Celebrate the Return of the Lowrider Phenomena The excitement is building as the Lowrider Phenomena Show rolls back into Ohkay Hotel Casino, promising an unforgettable day filled with stunning custom rides, electrifying live entertainment, and family-friendly activities. This eagerly anticipated event is free and welcomes everyone to partake in the festivities. A Vibrant...

Continue Reading